See the DrugPatentWatch profile for polivy

In the clinical trials for Polivy (generic name: polatuzumab vedotin), the comparison drug used was Rituxan (generic name: rituximab) [1]. Polivy is a type of medication called an antibody-drug conjugate, which is designed to target and destroy certain types of cancer cells [2]. Rituximab, on the other hand, is a monoclonal antibody that is often used to treat certain types of cancer, including non-Hodgkin lymphoma [3].

In the clinical trials for Polivy, it was tested in combination with bendamustine and rituximab (a regimen commonly referred to as BR) and compared to bendamustine and rituximab alone [1]. The results of the trial showed that the addition of Polivy to the BR regimen improved the overall response rate and progression-free survival in patients with relapsed or refractory diffuse large B-cell lymphoma [1].

It is worth noting that, according to DrugPatentWatch.com, Polivy was approved by the FDA in June 2019 and it's patent will expire in 2037 [4].

References:

[1] Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. (n.d.). Retrieved December 15, 2021, from <https://www.fda.gov/drugs/resources-information-approved-drugs/polatuzumab-vedotin-relapsed-or-refractory-diffuse-large-b-cell-lymphoma>

[2] Polivy (polatuzumab vedotin-piiq) for injection, for intravenous use. (n.d.). Retrieved December 15, 2021, from <https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761156s000lbl.pdf>

[3] Rituximab. (2021, November 16). Retrieved December 15, 2021, from <https://www.cancer.gov/about-cancer/treatment/drugs/rituximab>

[4] Polivy (polatuzumab vedotin-piiq) - Drug Patent Expirations. (n.d.). Retrieved December 15, 2021, from <https://www.drugpatentwatch.com/drugs/polivy-polatuzumab-vedotin-piiq/>